84 related articles for article (PubMed ID: 3747536)
1. [Information systems for phase III and IV clinical trials].
Alamercery Y; Begaud ; Chastang ; Derzko ; Dupuis Y; Gomeni R; Go L; Lemarie ; Mery ; Wartelle
J Pharmacol; 1986; 17 Suppl 1():12-8. PubMed ID: 3747536
[No Abstract] [Full Text] [Related]
2. Practical considerations in planning and conducting clinical trials with investigational or marketed drugs.
Spilker B
Clin Neuropharmacol; 1983; 6(4):325-47. PubMed ID: 6661731
[TBL] [Abstract][Full Text] [Related]
3. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
Glasser SP; Salas M; Delzell E
J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
[TBL] [Abstract][Full Text] [Related]
4. Systems validation for parenteral clinical drugs--application to R&D and QC laboratories.
Tetzlaff RF
J Parenter Sci Technol; 1983; 37(2):45-50. PubMed ID: 6345744
[No Abstract] [Full Text] [Related]
5. [Early identification of the tolerance profile of agents under clinical investigation].
Palminteri R; Sarazin E; Narbonne G
Therapie; 1987; 42(4):343-6. PubMed ID: 3317981
[No Abstract] [Full Text] [Related]
6. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
Falit BP
Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
[No Abstract] [Full Text] [Related]
7. [Drug control within the EEC II: good possibilities for Sweden].
Strandberg K
Lakartidningen; 1992 Jan; 89(4):178-9. PubMed ID: 1734147
[No Abstract] [Full Text] [Related]
8. [Activities of a regional drug monitoring center. What to evaluate, how and for what purpose].
Péré JC; Haramburu F; Bégaud B; Barat C; Laborde B; Albin H
Therapie; 1987; 42(4):351-8. PubMed ID: 3686468
[No Abstract] [Full Text] [Related]
9. Adverse drug reactions--when is an adverse drug reaction not an adverse drug reaction?
Leber P
Psychopharmacol Bull; 1982 Apr; 18(2):6-9. PubMed ID: 7051080
[No Abstract] [Full Text] [Related]
10. Laboratory tests during clinical trials.
Scand J Clin Lab Invest Suppl; 1989; 195():16-8. PubMed ID: 2799277
[No Abstract] [Full Text] [Related]
11. [Communication and transparency concerning risk-benefit analysis in public health: the example of medication].
Lehner JP; Meyer F; Juillet Y
Therapie; 2001; 56(4):335-9. PubMed ID: 11677849
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
13. [The GCP directive--consequences for clinical drug research].
Gluud CN
Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
[TBL] [Abstract][Full Text] [Related]
14. Cut adverse drug reactions with clinical decision support.
Maslakowski C
Health Manag Technol; 1996 Aug; 17(9):28-30. PubMed ID: 10172700
[No Abstract] [Full Text] [Related]
15. Most adverse drug events unreported: take these steps.
Hosp Peer Rev; 2007 Oct; 32(10):143-5. PubMed ID: 17957885
[No Abstract] [Full Text] [Related]
16. IFCC Guidelines to the Evaluation of Drug Effects in Clinical Chemistry. The basic concepts.
Scand J Clin Lab Invest Suppl; 1989; 195():5-6. PubMed ID: 2678422
[No Abstract] [Full Text] [Related]
17. Placebo in clinical drug trials--a multidisciplinary review.
Haegerstam G; Huitfeldt B; Nilsson BS; Sjövall J; Syvälahti E; Wahlén A
Methods Find Exp Clin Pharmacol; 1982; 4(4):261-78. PubMed ID: 6750286
[TBL] [Abstract][Full Text] [Related]
18. [The decisive steps cost billions. Extensive studies provide answers for many questions].
Wallström A; Rosén A; Keisu M
Lakartidningen; 1997 Jul; 94(30-31):2653-7. PubMed ID: 9273428
[No Abstract] [Full Text] [Related]
19. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
20. Choice of designs and doses for early phase trials.
Zhou Y
Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
